KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Change in Receivables (2016 - 2020)

Thermo Fisher Scientific filings provide 12 years of Change in Receivables readings, the most recent being $444.0 million for Q4 2020.

  • On a quarterly basis, Change in Receivables rose 562.5% to $444.0 million in Q4 2020 year-over-year; TTM through Dec 2020 was $1.3 billion, a 478.67% increase, with the full-year FY2025 number at $426.0 million, up 149.12% from a year prior.
  • Change in Receivables hit $444.0 million in Q4 2020 for Thermo Fisher Scientific, down from $663.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $663.0 million in Q3 2020 to a low of -$96.0 million in Q4 2019.
  • Median Change in Receivables over the past 5 years was $49.6 million (2016), compared with a mean of $130.4 million.
  • Biggest five-year swings in Change in Receivables: surged 7629.03% in 2016 and later crashed 230.77% in 2019.
  • Thermo Fisher Scientific's Change in Receivables stood at $239.6 million in 2016, then dropped by 16.11% to $201.0 million in 2017, then surged by 50.25% to $302.0 million in 2018, then tumbled by 131.79% to -$96.0 million in 2019, then soared by 562.5% to $444.0 million in 2020.
  • The last three reported values for Change in Receivables were $444.0 million (Q4 2020), $663.0 million (Q3 2020), and -$23.0 million (Q2 2020) per Business Quant data.